Company: PRTA
Filing Date: 2025-08-04
Form Type: 10-Q
Source: 0001559053-25-000031
Chunk: 37

Company: PROTHENA CORP PUBLIC LTD CO
Filing Date: 2025-08-04
Form: 10-Q
Item: Part I, Item 2
Chunk 37
---
83)                      —     
  Restructuring costs                                    32,609      —                                    32,609      nm    
  Total operating expenses        $                     157,445      $         155,215      $              2,230      1     

__________

n/m = not meaningful

Total operating expenses consist of R& D expenses, general and administrative (“ G& A”) expenses, and restructuring costs. Our operating expenses were $89.0 million and $73.6 million three months ended June 30, 2025 and2024, respectively, and $157.4 million a nd $155.2 million for the six months ended June 30, 2025, and 2024, respectively.

Our research activities are aimed at developing new drug products. Our development activities involve the translation of our research into potential new drugs. Our R& D expenses primarily consist of personnel costs and related expenses, including share-based compensation and external costs associated with clinical activities and drug development related to our drug programs, including birtamimab, PRX012, PRX019, and preclinical activities related to our discovery programs.

Our G& A expenses primarily consist of personnel costs and related expenses, including share-based compensation and consulting expenses.

Research and Development Expenses

Our R& D expense decrease d by $17.0 million or 30% for the three months ended June 30, 2025 and decreased b y $30.3 million or 25% for the six months ended June 30, 2025, compared to the same periods in the prior year. T he decrease for the three and six months ended June 30, 2025, compared to the same periods in the prior year, was primarily due to lower clinical trial expenses primarily related to PRX012, lower manufacturing expense and lower personnel expenses.

The following table sets forth the R& D expenses for our major programs (specifically, programs with successful first dosing in a Phase 1 clinical trial and have material expenditures in the periods presented), which were birtamimab, PRX012, PRX019, and other R& D expenses for the three and six months ended June 30, 2025, and 2024, (in thousands):

                                      Three Months Ended                                        Six Months Ended                           
                                      June 30,                                                  June 30,                                   
                                      2025                                2024                  2025                                       
 ─────────────────────────────────────────────────────────────────────────────────────────────────